Literature DB >> 24756661

The prevalence of personality disorder in a psychiatric and substance abuse population in Jamaica.

G Walcott1, J Martin2, F W Hickling3.   

Abstract

OBJECTIVE: To determine the prevalence of personality disorders in patients admitted to the psychiatric wards of the University Hospital of the West Indies (UHWI).
METHOD: Patients (n = 100) sequentially admitted to the psychiatric wards of the UHWI were assessed for personality disorder using the gold standard of a consultant assessment using the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision (DSM IV-TR) diagnostic criteria for personality disorder, the International Personality Disorder Examination Screening questionnaire (IPDE-S), and the Jamaica Personality Disorder Inventory (JPDI).
RESULTS: The three assessment instruments identified a prevalence of personality disorder in the cohort of patients of 51% consultant DSM-IV-TR assessment, 57% JPDI and 86% IPDE-S. The prevalence rate identified by the IPDE-S was significantly higher that the local instruments used (p < 0.000).
CONCLUSIONS: The prevalence of personality disorder assessed by the JPDI and the consultant DSM IV-TR instruments in Jamaica is comparable to the prevalence rate of studies in other countries in a similar population.

Entities:  

Mesh:

Year:  2013        PMID: 24756661     DOI: 10.7727/wimj.2013.078

Source DB:  PubMed          Journal:  West Indian Med J        ISSN: 0043-3144            Impact factor:   0.171


  2 in total

1.  Understanding the Relationship Between Complicated Grief Symptoms and Patterns of Personality Disorders in a Substance Users' Sample: A Network Analysis Approach.

Authors:  Laura Masferrer; Anthony D Mancini; Beatriz Caparrós
Journal:  Front Psychol       Date:  2020-10-30

2.  Risk of Suicide and Dysfunctional Patterns of Personality among Bereaved Substance Users.

Authors:  Laura Masferrer; Beatriz Caparrós
Journal:  Int J Environ Res Public Health       Date:  2017-03-20       Impact factor: 3.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.